FK506-binding protein 1A–calcineurin complex (FKBP12–CN complex)

The FKBP-12–calcineurin complex is a critical molecular assembly involved in the regulation of the adaptive immune response (UniProt P62942). It is formed when the immunosuppressant drug tacrolimus (FK506) binds to the 12 kDa FK506-binding protein (FKBP12), creating a composite surface that inhibits calcineurin, a calcium-dependent serine/threonine phosphatase (PubMed: 1703438). Under normal physiological conditions, calcineurin dephosphorylates the Nuclear Factor of Activated T-cells (NFAT), allowing it to enter the nucleus and initiate the transcription of cytokines like interleukin-2 (IL-2), which are essential for T-cell proliferation (StatPearls: NBK544318). By inhibiting this phosphatase activity, the FKBP-12–calcineurin complex effectively suppresses T-cell activation and the subsequent immune cascade (PubMed: 7545934). This mechanism is therapeutically exploited to prevent organ transplant rejection and treat various autoimmune and inflammatory conditions (NIH: PubChem CID 445643). However, because calcineurin is expressed in non-immune tissues, targeting this complex is associated with significant side effects, including nephrotoxicity and neurotoxicity (PubMed: 19158130).

Other names

FKBP12-calcineurin complexFKBP1A-calcineurin complexTacrolimus-FKBP12-calcineurin complexFK506-FKBP12-calcineurin complex

Tacrolimus binds to the immunophilin FKBP12, forming a drug-protein complex that subsequently binds to and inhibits the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation of the transcription factor NFAT (Nuclear Factor of Activated T-cells), thereby blocking its translocation into the nucleus and suppressing the transcription of pro-inflammatory cytokines such as interleukin-2 (IL-2) (StatPearls: NBK544318; PubMed: 1703438).